EP2215261B1 - Procédé de diagnostic de néoplasmes - Google Patents
Procédé de diagnostic de néoplasmes Download PDFInfo
- Publication number
- EP2215261B1 EP2215261B1 EP08843297.6A EP08843297A EP2215261B1 EP 2215261 B1 EP2215261 B1 EP 2215261B1 EP 08843297 A EP08843297 A EP 08843297A EP 2215261 B1 EP2215261 B1 EP 2215261B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequence
- seq
- similarity
- length
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 113
- 206010028980 Neoplasm Diseases 0.000 title description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 208
- 230000014509 gene expression Effects 0.000 claims description 161
- 108090000623 proteins and genes Proteins 0.000 claims description 102
- 208000003200 Adenoma Diseases 0.000 claims description 97
- 239000000523 sample Substances 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 73
- 230000001613 neoplastic effect Effects 0.000 claims description 73
- 206010001233 Adenoma benign Diseases 0.000 claims description 55
- 239000012472 biological sample Substances 0.000 claims description 51
- 208000009956 adenocarcinoma Diseases 0.000 claims description 47
- 238000012216 screening Methods 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 33
- 210000002429 large intestine Anatomy 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 210000005170 neoplastic cell Anatomy 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 241000792859 Enema Species 0.000 claims description 5
- 239000007920 enema Substances 0.000 claims description 5
- 229940095399 enema Drugs 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000002271 resection Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 description 125
- 210000001519 tissue Anatomy 0.000 description 64
- 150000007523 nucleic acids Chemical class 0.000 description 55
- 238000009396 hybridization Methods 0.000 description 53
- 102000039446 nucleic acids Human genes 0.000 description 47
- 108020004707 nucleic acids Proteins 0.000 description 47
- 239000000047 product Substances 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 29
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 239000003550 marker Substances 0.000 description 25
- 238000009739 binding Methods 0.000 description 23
- 238000001514 detection method Methods 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 210000001072 colon Anatomy 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 21
- 238000002493 microarray Methods 0.000 description 21
- 239000013615 primer Substances 0.000 description 21
- 238000005259 measurement Methods 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 230000009826 neoplastic cell growth Effects 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 15
- 239000002157 polynucleotide Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000008685 targeting Effects 0.000 description 14
- 239000003155 DNA primer Substances 0.000 description 12
- 108700024394 Exon Proteins 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- -1 etc) Substances 0.000 description 10
- 239000002853 nucleic acid probe Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 201000002758 colorectal adenoma Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108010090804 Streptavidin Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 208000035269 cancer or benign tumor Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 206010058314 Dysplasia Diseases 0.000 description 6
- 108010033040 Histones Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000007067 DNA methylation Effects 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 238000002052 colonoscopy Methods 0.000 description 5
- 230000000762 glandular Effects 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 206010048832 Colon adenoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100033636 Histone H3.2 Human genes 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- JTLDBJGKDYQKGB-UHFFFAOYSA-N 3,4-bis(4-methoxyphenyl)-2-methylbenzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C(C)=C1C1=CC=C(OC)C=C1 JTLDBJGKDYQKGB-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- OEXZVWQQTFVIDS-UHFFFAOYSA-N 2-(chloromethyl)-3,4-bis(4-methoxyphenyl)benzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C(CCl)=C1C1=CC=C(OC)C=C1 OEXZVWQQTFVIDS-UHFFFAOYSA-N 0.000 description 1
- DWWYUMNNFKUIJS-UHFFFAOYSA-N 2-(hydroxymethyl)-3,4-bis(4-methoxyphenyl)benzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C(CO)=C1C1=CC=C(OC)C=C1 DWWYUMNNFKUIJS-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710180995 Endonuclease 1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 102100040296 TATA-box-binding protein Human genes 0.000 description 1
- 101710145783 TATA-box-binding protein Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 201000003785 large intestine adenocarcinoma Diseases 0.000 description 1
- 201000003782 large intestine adenoma Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000021006 low vegetable intake Nutrition 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000019694 serous adenocarcinoma Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
Definitions
- the present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma.
- the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas.
- the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers.
- Adenomas are benign tumours, or neoplasms, of epithelial origin which are derived from glandular tissue or exhibit clearly defined glandular structures. Some adenomas show recognisable tissue elements, such as fibrous tissue (fibroadenomas) and epithelial structure, while others, such as bronchial adenomas, produce active compounds that might give rise to clinical syndromes.
- Adenomas may progress to become an invasive neoplasm and are then termed adenocarcinomas.
- adenocarcinomas are defined as malignant epithelial tumours arising from glandular structures, which are constituent parts of many organs of the body.
- the term adenocarcinoma is also applied to tumours showing a glandular growth pattern. These tumours may be sub-classified according to the substances that they produce, for example mucus secreting and serous adenocarcinomas, or to the microscopic arrangement of their cells into patterns, for example papillary and follicular adenocarcinomas.
- These carcinomas may be solid or cystic (cystadenocarcinomas).
- Each organ may produce tumours showing a variety of histological types, for example the ovary may produce both mucinous and cystadenocarcinoma.
- Adenomas in different organs behave differently.
- the overall chance of carcinoma being present within an adenoma i.e. a focus of cancer having developed within a benign lesion
- this is related to size of an adenoma.
- occurrence of a cancer within an adenoma is rare in adenomas of less than 1 centimetre.
- Such a development is estimated at 40 to 50% in adenomas which are greater than 4 centimetres and show certain histopathological change such as villous change, or high grade dysplasia.
- Adenomas with higher degrees of dysplasia have a higher incidence of carcinoma.
- the predictors of the presence of cancer now or the future occurrence of cancer in the organ include size (especially greater than 9mm) degree of change from tubular to villous morphology, presence of high grade dysplasia and the morphological change described as "serrated adenoma".
- the additional features of increasing age, familial occurrence of colorectal adenoma or cancer, male gender or multiplicity of adenomas predict a future increased risk for cancer in the organ - so-called risk factors for cancer. Except for the presence of adenomas and its size, none of these is objectively defined and all those other than number and size are subject to observer error and to confusion as to precise definition of the feature in question. Because such factors can be difficult to assess and define, their value as predictors of current or future risk for cancer is imprecise.
- Colorectal adenomas represent a class of adenomas which are exhibiting an increasing incidence, particularly in more affluent countries.
- the causes of adenoma, and of progression to adenocarcinoma, are still the subject of intensive research.
- environmental factors such as diet
- Colonic adenomas are localised areas of dysplastic epithelium which initially involve just one or several crypts and may not protrude from the surface, but with increased growth in size, usually resulting from an imbalance in proliferation and/or apoptosis, they may protrude.
- Adenomas can be classified in several ways. One is by their gross appearance and the major descriptors include degrees of protrusion: flat sessile (i.e. protruding but without a distinct stalk) or pedunculated (i.e. having a stalk). Other gross descriptors include actual size in the largest dimension and actual number in the colon/rectum.
- adenomas While small adenomas (less than say 5 or 10 millimetres) exhibit a smooth tan surface, pedunculated and especially larger adenomas tend to have a cobblestone or lobulated red-brown surface. Larger sessile adenomas may exhibit a more delicate villous surface.
- Another set of descriptors include the histopathological classification; the prime descriptors of clinical value include degree of dysplasia (low or high), whether or not a focus of invasive cancer is present, degree of change from tubular gland formation to villous gland formation (hence classification is tubular, villous or tubulovillous), presence of admixed hyperplastic change and of so-called "serrated" adenomas and its subgroups. Adenomas can be situated at any site in the colon and/or rectum although they tend to be more common in the rectum and distal colon. All of these descriptors, with the exception of number and size, are relatively subjective and subject to interobserver disagreement.
- adenomas are of value not just to ascertain the neoplastic status of any given adenomas when detected, but also to predict a person's future risk of developing colorectal adenomas or cancer.
- Those features of an adenoma or number of adenomas in an individual that point to an increased future risk for cancer or recurrence of new adenomas include: size of the largest adenoma (especially 10mm or larger), degree of villous change (especially at least 25% such change and particularly 100% such change), high grade dysplasia, number (3 or more of any size or histological status) or presence of serrated adenoma features.
- risk None except size or number is objective and all are relatively subjective and subject to interobserver disagreement. These predictors of risk for future neoplasia (hence "risk”) are vital in practice because they are used to determine the rate and need for and frequency of future colonoscopic surveillance. More accurate risk classification might thus reduce workload of colonoscopy, make it more cost-effective and reduce the risk of complications from unnecessary procedures.
- Adenomas are generally asymptomatic, therefore rendering difficult their diagnosis and treatment at a stage prior to when they might develop invasive characteristics and so became cancer. It is technically impossible to predict the presence or absence of carcinoma based on the gross appearance of adenomas, although larger adenomas are more likely to show a region of malignant change than are smaller adenomas. Sessile adenomas exhibit a higher incidence of malignancy than pedunculated adenomas of the same size. Some adenomas result in blood loss which might be observed or detectable in the stools; while sometimes visible by eye, it is often, when it occurs, microscopic or "occult". Larger adenomas tend to bleed more than smaller adenomas.
- the identification of molecular markers for adenomas would provide means for understanding the cause of adenomas and cancer, improving diagnosis of adenomas including development of useful screening tests, elucidating the histological state of an adenoma, characterising a patient's future risk for colorectal neoplasia on the basis of the molecular state of an adenoma and facilitating treatment of adenomas.
- Yoshida R, et al (Genome Inform (2006), Vol 17, No.1, pp 88-89 ) tested a statistical analysis of splice variations in exon microarray data, with a view to identifying specific splicing events that are observed in certain cells such a tumour cells.
- this gene which comprises SEQ ID NO:1 and is herein called hCG_1815491, encodes 18 identified exon segments, several of which are expressed in two or more splice variants forms.
- hCG_1815491 has now been found to transcribe to at least 11 variant RNA transcript forms.
- hCG_1815491 has still further been determined that although the levels of multiple transcribed forms of hCG_1815491 show some level of increase in expression in the context of neoplasia development, hCG_1815491 is, in fact, alternatively spliced in a neoplastic specific manner, thereby enabling a level of diagnostic and prognostic discrimination which is rarely available in the context of a single gene and has been unavailable in terms of the diagnosis of colorectal neoplasias.
- the findings of the present invention have therefore facilitated the development of a screening method to diagnose the onset, or predisposition thereto, of adenocarcinoma, adenoma and/or the monitoring of conditions characterised by the development of these types of neoplasms.
- the term "derived from” shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source. Further, as used herein the singular forms of "a”, “and” and “the” include plural referents unless the context clearly dictates otherwise.
- the subject specification contains amino acid and nucleotide sequence information prepared using the programme PatentIn Version 3.4, presented herein after the bibliography.
- Each amino acid and nucleotide sequence is identified in the sequence listing by the numeric indicator ⁇ 210> followed by the sequence identifier (eg. ⁇ 210>1, ⁇ 210>2, etc).
- the length, type of sequence (amino acid, DNA, etc.) and source organism for each sequence is indicated by information provided in the numeric indicator fields ⁇ 211>m ⁇ 212> and ⁇ 213>, respectively.
- Amino acid and nucleotide sequences referred to in the specification are identified by the Indicator SEQ ID NO: followed by the sequence identifier (eg. SEQ ID NO:1, SEQ ID NO: 2, etc).
- sequence identifier referred to in the specification correlates to the Information provided in numeric indicator field ⁇ 400> in the sequence listing, which is followed by the sequence identifier (eg. ⁇ 400>1, ⁇ 400>2, etc). That is SEQ ID NO: I as detailed In the specification correlates to the sequence indicated as ⁇ 400>1 in the sequence listing.
- One aspect of the present invention is directed to a method of screening for the onset or predisposition to the onset of a large intestine neoplasm in an individual, said method comprising measuring the level of expression of hCG_1815491 in a biological sample from said individual wherein a higher level of expression of hCG_1815491 or variant thereof relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.
- the present invention more particularly provides a method of screening for the onset or predisposition to the onset of a large intestine neoplasm in an individual, said method comprising measuring the level of expression of a gene comprising a sequence of nucleotides as set forth in SEQ ID NO:1 or a sequence having at least 90% similarity to SEQ ID NO:1 across the length of the gene, or variant of SEQ ID NO:1, in a biological sample from said individual wherein a higher level of expression of said gene or variant thereof relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.
- Another aspect of the present invention provides a method of screening for the onset or predisposition to the onset of a large intestine neoplasm in an individual, said method comprising measuring the level of expression of one or more RNA transcripts, which transcripts comprise an RNA sequence characterised by the sequence of one of:
- RNA transcript the level of expression of which is assessed in accordance with the method of the present invention, is one or more of the transcripts characterised by the sequence of one of:
- RNA transcript which transcript comprises one or more exon segments selected from:
- RNA transcript which transcript comprises one or more exon segments selected from:
- RNA transcript selected from:
- RNA transcript which transcript is selected from:
- RNA transcripts which transcripts comprise an RNA sequence characterised by the sequence of one of:
- Still another aspect of the present invention provides a diagnostic kit for assaying biological samples comprising an agent for detecting one or more neoplastic marker reagents useful for facilitating the detection by the agent in the first compartment. Further means may also be included, for example, to receive a biological sample.
- the agent may be any suitable detecting molecule.
- the present invention is predicated, in part, on the elucidation of a gene expression profile, specifically that of hCG_1815491, which characterises large intestine cellular populations in terms of their neoplastic state.
- This finding has now facilitated the development of routine means of screening for the onset or predisposition to the onset of a large intestine neoplasm based on screening for upregulation of the expression of this molecule, relative to control expression levels.
- hCG_1815491 in addition to assessing expression levels of hCG_1815491 relative to normal or non-neoplastic levels, it has been determined that hCG_1815491 is alternatively spliced in a neoplastic specific manner, thereby enabling a high level of discrimination.
- hCG_1815491 is modulated, in terms of differential changes to its levels of expression, depending on whether the cell expressing that gene is neoplastic or not.
- reference to a gene "expression product” or “expression of a gene” is a reference to either a transcription product (such as primary RNA or mRNA) or a translation product such as protein. This gene and its expression products, whether they be RNA transcripts or encoded proteins, are collectively referred to as the "neoplastic marker".
- one aspect of the present invention is directed to a method of screening for the onset or predisposition to the onset of a large intestine neoplasm in an individual, said method comprising measuring the level of expression of hCG_1815491 in a biological sample from said individual wherein a higher level of expression of hCG_1815491 or variant thereof relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.
- neoplasm should be understood as a reference to a lesion, tumour or other encapsulated or unencapsulated mass or other form of growth which comprises neoplastic cells.
- a “neoplastic cell” should be understood as a reference to a cell exhibiting abnormal growth.
- growth should be understood in its broadest sense and includes reference to proliferation.
- an example of abnormal cell growth is the uncontrolled proliferation of a cell.
- Another example is failed apoptosis in a cell, thus prolonging its usual life span.
- the neoplastic cell may be a benign cell or a malignant cell.
- the subject neoplasm is an adenoma or an adenocarcinoma.
- an adenoma is generally a benign tumour of epithelial origin which is either derived from epithelial tissue or exhibits clearly defined epithelial structures. These structures may take on a glandular appearance. It can comprise a malignant cell population within the adenoma, such as occurs with the progression of a benign adenoma to a malignant adenocarcinoma.
- said neoplastic cell is an adenoma or adenocarcinoma and even more preferably a colorectal adenoma or adenocarcinoma.
- hCG_1815491 and its transcribed and translated expression products should be understood as a reference to all forms of this gene and to fragments thereof. As would be appreciated by the person of skill in the art, genes are known to exhibit allelic or polymorphic variation between individuals. Accordingly, reference to “hCG_1815491” should be understood to extend to such variants which, in terms of the present diagnostic applications, achieve the same outcome despite the fact that minor genetic variations between the actual nucleic acid sequences may exist between individuals. Reference to “variants” should also be understood to extend to alternative transcriptional forms of hCG_1815491, such as splice variants or variants which otherwise exhibit variation to exon expression and arrangement, such as in terms of multiple exon combinations or alternate 5'- or 3'- ends.
- RNA eg mRNA, primary RNA transcript, miRNA, etc
- cDNA e.g. cDNA
- peptide isoforms which arise from alternative splicing or any other mutation, polymorphic or allelic variation. It should also be understood to include reference to any subunit polypeptides such as precursor forms which may be generated, whether existing as a monomer, multimer, fusion protein or other complex.
- the hCG_1815491 genomic sequence comprises SEQ ID NO:1.
- the SEQ ID NO:1 nucleic acid molecule has been determined to generate at least 18 alternatively spliced exon segments, as follows:
- SEQ ID NO:1 has at least 8 putative exon segments (SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO:20) of which several are alternatively spliced. It has been still further determined that from this genomic structure there are transcribed at least 11 different RNA transcripts which each comprise one of the sequences depicted in SEQ ID NOs:21-31, Table 1 and are schematically depicted in Figure 4 . It would be appreciated that the sequences which are depicted in SEQ ID NOs:21-31 take the form of DNA since they have been assembled using SEQ ID NO: 1. However, the RNA transcripts which are generated either in vivo or in vitro would be characterised by comprising a corresponding sequence, albeit in RNA form.
- screening for the "level of expression" of hCG_1815491 may be achieved in a variety of ways including screening for any of the forms of RNA transcribed from hCG_1815491, cDNA generated therefrom or a protein expression product. Changes to the levels of any of these products is indicative of changes to the expression of the subject gene. Still further, the molecule which is identified and measured may be a whole molecule or a fragment thereof.
- fragmented hCG_1815491 molecules are useful in the context of the method of the present invention.
- identification of RNA transcripts corresponding to one or more of the exon segments herein defined, alone or in combination, is a useful means of screening for changes to hCG_1815491 expression.
- the present invention therefore more particularly provides a method of screening for the onset of a large intestine neoplasm in an individual, said method comprising measuring the level of expression of a gene comprising a sequence of nucleotides as set forth in SEQ ID NO:1 or a sequence having at least 90% similarity to SEQ ID NO:1 across the length of the gene, or variant of SEQ ID NO:1, in a biological sample from said individual wherein a higher level of expression of said gene or variant thereof relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.
- RNA transcripts from one or more promoters, including transcripts formed by the splicing of two or more exons as hereinbefore described. It would be appreciated that not all RNA transcripts are necessarily translated to a protein expression product.
- said hCG_1815491 expression levels are assessed by screening for the levels of expression of one or more of the RNA transcripts which are generated from the SEQ ID NO:1 genomic sequence.
- RNA transcripts which transcripts comprise an RNA sequence characterised by the sequence of one of:
- RNA transcript being "characterised by" the sequence of any one of SEQ ID NOs:21-31 should be understood to mean that the subject RNA transcript comprises a corresponding RNA form of the DNA sequence information which is depicted in SEQ ID NOs:21-31. That is, each of the DNA nucleotides depicted in these sequences should be replaced with the corresponding RNA version of that nucleotide.
- the RNA transcript is one or more of the transcripts characterised by the sequence of one of:
- RNA transcript is one or more of the transcripts characterised by the sequence of one of:
- RNA transcript is characterised by SEQ ID NO:2.
- RNA transcript itself or for an expression product translated from said RNA transcript. It should be understood that one may choose to screen for any one or more of said transcripts in a single sample of interest.
- hCG_1815491 has been determined to comprise 18 alternatively spliced exon segments which give rise to at least 11 RNA transcripts. It has now been determined that screening for the expression of one or more of the exon segments themselves is indicative of the neoplastic state of the individual in issue. It has still further been determined that the identification of certain combinations of these exons is particularly useful in this regard. To this end, it should be appreciated that the specific exon combinations which are hereinafter discussed may, in some RNA transcripts, have been spliced such that they are joined. In other transcripts, the subject exons may not be joined to one another but may be positioned, relative to one another, either proximally or distally along the transcript.
- RNA transcript which transcript comprises one or more exon segments selected from:
- RNA transcript which transcript comprises one or more exon segments selected from:
- RNA transcript selected from:
- RNA transcript which transcript comprises one or more exon segments selected from:
- RNA transcript which transcript is selected from:
- exon segments of said transcripts are spliced such that they are joined.
- sequence similarity also referred to as “identity”
- terms used to describe sequence relationships between two or more polynucleotides include “reference sequence”, “comparison window”, “sequence similarity”, “sequence identity”, “percentage of sequence similarity”, “percentage of sequence identity”, “substantially similar” and “substantial identity”.
- a “reference sequence” is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units in length. Because two polynucleotides may each comprise (1) a sequence (i.e.
- sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.
- a “comparison window” refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence.
- the comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected.
- GAP Garnier et al.
- Altschul et al. Nucl. Acids Res. 25: 3389, 1997
- a detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al. ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, Chapter 15, 1994-1998 ).
- a range of other algorithms may be used to compare the nucleotide and amino acid sequences such as but not limited to PILEUP, CLUSTALW, SEQUENCHER or VectorNTI.
- sequence similarity and “sequence identity” as used herein refers to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis over a window of comparison.
- a “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- sequence identity will be understood to mean the “match percentage” calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.
- nucleic acid sequence identities may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art.
- the extent of sequence identity may be determined using any computer program and associated parameters, including those described herein, such as BLAST 2.2.2. or FASTA version 3.0t78, with the default parameters.
- sequence comparison algorithm is a BLAST version algorithm.
- Exemplary algorithms and programs include, but are not limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW ( Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8):2444-2448, 1988 ; Altschul et al., J. Mol. Biol. 215(3):403-410, 1990 ; Thompson et al., Nucleic Acids Res. 22(2):4673-4680, 1994 ; Higgins et al., Methods Enzymol. 266:383-402, 1996 ; Altschul et al., Nature Genetics 3:266-272, 1993 ).
- sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705.
- sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705.
- BLAST, BLAST 2.0 and BLAST 2.2.2 algorithms are also used to practice the invention. They are described, e.g., in ; Altschul et al. (1990), supra. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al. (1990) supra ). These initial neighbourhood word hits act as seeds for initiating searches to find longer HSPs containing them.
- HSPs high scoring sequence pairs
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873 ).
- One measure of similarity provided by BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance.
- the subject sequences are defined as exhibiting at least 90% similarity.
- said percentage similarity is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 %or 99%.
- the "individual" who is the subject of testing may be any human or non-human mammal.
- non-human mammals includes primates, livestock animals (e.g. horses, cattle, sheep, pigs, donkeys), laboratory test animals (e.g. mice, rats, rabbits, guinea pigs), companion animals (e.g. dogs, cats) and captive wild animals (e.g. deer, foxes).
- livestock animals e.g. horses, cattle, sheep, pigs, donkeys
- laboratory test animals e.g. mice, rats, rabbits, guinea pigs
- companion animals e.g. dogs, cats
- captive wild animals e.g. deer, foxes
- control level may be either a "normal level", which is the level of marker expressed by a corresponding large intestine cell or cellular population which is not neoplastic, or the background level which is detectable in a negative control sample.
- the normal (or "non-neoplastic" level may be determined using tissues derived from the same individual who is the subject of testing. However, it would be appreciated that this may be quite invasive for the individual concerned and it is therefore likely to be more convenient to analyse the test results relative to a standard result which reflects individual or collective results obtained from individuals other than the patient in issue. This latter form of analysis is in fact the preferred method of analysis since it enables the design of kits which require the collection and analysis of a single biological sample, being a test sample of interest.
- the standard results which provide the normal level may be calculated by any suitable means which would be well known to the person of skill in the art.
- a population of normal tissues can be assessed in terms of the level of the neoplastic marker of the present invention, thereby providing a standard value or range of values against which all future test samples are analysed.
- the normal level may be determined from the subjects of a specific cohort and for use with respect to test samples derived from that cohort. Accordingly, there may be determined a number of standard values or ranges which correspond to cohorts which differ in respect of characteristics such as age, gender, ethnicity or health status.
- Said "normal level” may be a discrete level or a range of levels. An increase in the expression level of the subject genes relative to normal levels is indicative of the tissue being neoplastic.
- control level is a non-neoplastic level.
- said large intestine tissue is preferably colorectal tissue.
- said neoplasm is a colorectal adenoma or adenocarcinoma.
- hCG_1815491 markers are not only expressed at levels higher than normal levels, their expression pattern is uniquely characterised by the fact that expression levels above that of background control levels are not detectable in non-neoplastic tissue.
- control level is therefore the "background level”.
- said background level is of the chosen testing methodology.
- RNA transcripts which transcripts comprise an RNA sequence characterised by the sequence of one of:
- said transcripts comprise an RNA sequence characterised by the sequence of one of:
- RNA sequences are characterised by the sequence of either SEQ ID NO:21 or SEQ ID NO:22.
- the detection method of the present invention can be performed on any suitable biological sample.
- a biological sample should be understood as a reference to any sample of biological material derived from an animal such as, but not limited to, cellular material, biological fluids (eg. blood), faeces, tissue biopsy specimens, surgical specimens or fluid which has been introduced into the body of an animal and subsequently removed (such as, for example, the solution retrieved from an enema wash).
- the biological sample which is tested according to the method of the present invention may be tested directly or may require some form of treatment prior to testing. For example, a biopsy or surgical sample may require homogenisation prior to testing or it may require sectioning for in situ testing of the qualitative expression levels of individual genes.
- a cell sample may require permeabilisation prior to testing. Further, to the extent that the biological sample is not in liquid form, (if such form is required for testing) it may require the addition of a reagent, such as a buffer, to mobilise the sample.
- a reagent such as a buffer
- the biological sample may be directly tested or else all or some of the nucleic acid or protein material present in the biological sample may be isolated prior to testing.
- the sample may be partially purified or otherwise enriched prior to analysis. For example, to the extent that a biological sample comprises a very diverse cell population, it may be desirable to enrich for a sub-population of particular interest.
- the target cell population or molecules derived therefrom pretreated prior to testing, for example, inactivation of live virus or being run on a gel. It should also be understood that the biological sample may be freshly harvested or it may have been stored (for example by freezing) prior to testing or otherwise treated prior to testing (such as by undergoing culturing).
- said sample is a faecal (stool) sample, enema wash, surgical resection, tissue biopsy or blood sample.
- the present invention is designed to screen for a neoplastic cell or cellular population, which is located in the large intestine.
- cell or cellular population should be understood as a reference to an individual cell or a group of cells.
- Said group of cells may be a diffuse population of cells, a cell suspension, an encapsulated population of cells or a population of cells which take the form of tissue.
- RNA transcripts eg primary RNA or mRNA
- Reference to "RNA” should be understood to encompass reference to any form of RNA, such as primary RNA or mRNA. Without limiting the present invention in any way, the modulation of gene transcription leading to increased or decreased RNA synthesis will also correlate with the translation of some of these RNA transcripts to produce a protein product.
- the present invention also extends to detection methodology which is directed to screening for modulated levels or patterns of the neoplastic marker protein products as an indicator of the neoplastic state of a cell or cellular population.
- detection methodology which is directed to screening for modulated levels or patterns of the neoplastic marker protein products as an indicator of the neoplastic state of a cell or cellular population.
- one method is to screen for RNA transcripts and/or the corresponding protein product
- the present invention is not limited in this regard and extends to screening for any other form of neoplastic marker expression product such as, for example, a primary RNA transcript. It is well within the skill of the person of skill in the art to determine the most appropriate screening target for any given situation.
- nucleic acid molecule should be understood as a reference to both deoxyribonucleic acid molecules and ribonucleic acid molecules and fragments thereof.
- the present invention therefore extends to both directly screening for RNA levels in a biological sample or screening for the complementary cDNA which has been reverse-transcribed from an RNA population of interest. It is well within the skill of the person of skill in the art to design methodology directed to screening for either DNA or RNA. As detailed above, the method of the present invention also extends to screening for the protein product translated from the subject RNA.
- protein should be understood to encompass peptides, polypeptides and proteins (including protein fragments).
- the protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.
- Reference herein to a "protein” includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.
- the proteins encoded by hCG_1815491 may be in multimeric form meaning that two or more molecules are associated together. Where the same protein molecules are associated together, the complex is a homomultimer.
- An example of a homomultimer is a homodimer.
- the complex is a heteromultimer such as a heterodimer.
- fragment should be understood as a reference to a portion of the subject nucleic acid molecule or protein. As detailed hereinbefore, this is particularly relevant with respect to screening for modulated RNA levels in stool samples since the subject RNA is likely to have been degraded or otherwise fragmented due to the environment of the gut. One may therefore actually be detecting fragments of the subject RNA molecule, which fragments are identified by virtue of the use of a suitably specific probe.
- references to the "onset" of a neoplasm should be understood as a reference to one or more cells of that individual exhibiting dysplasia.
- the adenoma or adenocarcinoma may be well developed in that a mass of dysplastic cells has developed.
- the adenoma or adenocarcinoma may be at a very early stage in that only relatively few abnormal cell divisions have occurred at the time of diagnosis.
- the present invention also extends to the assessment of an individual's predisposition to the development of a neoplasm, such as an adenoma or adenocarcinoma.
- changed levels of the neoplastic marker may be indicative of that individual's predisposition to developing a neoplasia, such as the future development of an adenoma or adenocarcinoma or another adenoma or adenocarcinoma.
- the detection of converse changes in the levels of said marker may be desired under certain circumstances, for example, to monitor the effectiveness of therapeutic or prophylactic treatment directed to modulating a neoplastic condition, such as adenoma or adenocarcinoma development.
- a neoplastic condition such as adenoma or adenocarcinoma development.
- a neoplastic condition such as adenoma or adenocarcinoma development
- screening for a decrease in the levels of this marker subsequently to the onset of a therapeutic regime may be utilised to indicate reversal or other form of improvement of the subject individual's condition.
- the method of the present invention is therefore useful as a one off test or as an on-going monitor of those individuals thought to be at risk of neoplasia development or as a monitor of the effectiveness of therapeutic or prophylactic treatment regimes directed to inhibiting or otherwise slowing neoplasia development.
- mapping the modulation of hCG_1815491 expression levels in any one or more classes of biological samples is a valuable indicator of the status of an individual or the effectiveness of a therapeutic or prophylactic regime which is currently in use.
- the method of the present invention should be understood to extend to monitoring for increases or decreases in hCG_1815491 expression levels in an individual relative to their normal level (as hereinbefore defined), or relative to one or more earlier marker expression levels determined from a biological sample of said individual.
- Means of testing for the subject expressed neoplasm marker in a biological sample can be achieved by any suitable method, which would be well known to the person of skill in the art, such as but not limited to:
- gene expression levels can be measured by a variety of methods known in the art.
- gene transcription or translation products can be measured.
- Gene transcription products, i.e., RNA can be measured, for example, by hybridization assays, run-off assays., Northern blots, or other methods known in the art.
- Hybridization assays generally involve the use of oligonucleotide probes that hybridize to the single-stranded RNA transcription products.
- the oligonucleotide probes are complementary to the transcribed RNA expression product.
- a sequence-specific probe can be directed to hybridize to RNA or cDNA.
- a "nucleic acid probe”, as used herein, can be a DNA probe or an RNA probe that hybridizes to a complementary sequence.
- One of skill in the art would know how to design such a probe such that sequence specific hybridization will occur.
- One of skill in the art will further know how to quantify the amount of sequence specific hybridization as a measure of the amount of gene expression for the gene was transcribed to produce the specific RNA.
- hybridization sample is maintained under conditions that are sufficient to allow specific hybridization of the nucleic acid probe to a specific gene expression product.
- Specific hybridization indicates near exact hybridization (e.g., with few if any mismatches).
- Specific hybridization can be performed under high stringency conditions or moderate stringency conditions.
- the hybridization conditions for specific hybridization are high stringency. For example, certain high stringency conditions can be used to distinguish perfectly complementary nucleic acids from those of less complementarity.
- the exact conditions that determine the stringency of hybridization depend not only on ionic strength (e.g., 0.2.times.SSC, 0.1.times.SSC), temperature (e.g., room temperature, 42°C., 68°C.) and the concentration of destabilizing agents such as formamide or denaturing agents such as SDS, but also on factors such as the length of the nucleic acid sequence, base composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences.
- equivalent conditions can be determined by varying one or more of these parameters while maintaining a similar degree of identity or similarity between the two nucleic acid molecules.
- conditions are used such that sequences at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 95% or more identical to each other remain hybridized to one another.
- hybridization conditions from a level of stringency at which no Hybridization occurs to a level at which hybridization is first observed, conditions that will allow a given sequence to hybridize (e.g., selectively) with the most complementary sequences in the sample can be determine.
- washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which only homologous hybridization occurs, each °C. by which the final wash temperature is reduced (holding SSC concentration constant) allows an increase by 1% in the maximum mismatch percentage among the sequences that hybridize. Generally, doubling the concentration of SSC results in an increase in T m of about 17°C.
- the wash temperature can be determined empirically for high, moderate or low stringency, depending on the level of mismatch sought.
- a low stringency wash can comprise washing in a solution containing 0,2,times.SSC/0.1% SDS for 10 minutes at room temperature
- a moderate stringency wash can comprise washing in a pre-warmed solution (42°C) solution containing 0.2.times.SSC/0.1% SDS for 15 minutes at 42°C.
- n high stringency wash can comprise washing in pre-warmed (68°C.) solution containing 0.1.times.SSC/0.1% SDS for 15 minute at 68°C.
- washes can be performed repeatedly or sequentially to obtain a desired result as known in the art.
- Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, write maintaining a similar degree of complementarity between the target nucleic acid molecule and the primer or probe used (e.g., the sequence to be hybridized).
- a related aspect of the present invention provides a molecular array, which array comprises a plurality of:
- said percent identity is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- Low stringency includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.
- Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31 % v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.
- the T m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatched based pairs ( Bonner et al (1973) J. Mol. Biol. 81:123 ).
- the subject probes are designed to bind to the nucleic acid or protein to which they are directed with a level of specificity which minimises the incidence of non-specific reactivity.
- a level of specificity which minimises the incidence of non-specific reactivity.
- probes which are used to detect the subject proteins may take any suitable form including antibodies and aptamers.
- a library or array of nucleic acid or protein probes provides rich and highly valuable information. Further, two or more arrays or profiles (information obtained from use of an array) of such sequences are useful tools for comparing a test set of results with a reference, such as another sample or stored calibrator. In using an array, individual probes typically are immobilized at separate locations and allowed to react for binding reactions. Oligonucleotide primers associated with assembled sets of markers are useful for either preparing libraries of sequences or directly detecting markers from other biological samples.
- a library (or array, when referring to physically separated nucleic acids corresponding to at least some sequences in a library) of hCG_1815491 markers exhibits highly desirable properties. These properties are associated with specific conditions, and may be characterized as regulatory profiles.
- a profile as termed here refers to a set of members that provides diagnostic information of the tissue from which the markers were originally derived. A profile in many instances comprises a series of spots on an array made from deposited sequences.
- a molecular array which array comprises a plurality of:
- a characteristic patient profile is generally prepared by use of an array.
- An array profile may be compared with one or more other array profiles or other reference profiles.
- the comparative results can provide rich information pertaining to disease states, developmental state, receptiveness to therapy and other information about the patient.
- Another aspect of the present invention provides a diagnostic kit for assaying biological samples comprising an agent for detecting one or more neoplastic marker reagents useful for facilitating the detection by the agent in the first compartment. Further means may also be included, for example, to receive a biological sample.
- the agent may be any suitable detecting molecule.
- RNA extractions were performed using Trizol(R)reagent (Invitrogen, Carlsbad, CA, USA) as per manufacturer's instructions. Each sample was homogenised in 300 ⁇ L of Trizol reagent using a modified dremel drill and sterilised disposable pestles. Additional 200 ⁇ L of Trizol reagent was added to the homogenate and samples were incubated at RT for 10 minutes. 100 ⁇ L of chloroform was then added, samples were shaken vortexed for 15 seconds, and incubated at RT for 3 further minutes. The aqueous phase containg target RNA was obtained by centrifugation at 12,000 rpm for 15 min, 40° C.
- Gene Chips were processed using the standard Affymetrix protocol developed for the HU Gene ST 1.0 array described in [Affymetrix, 2007]. Briefly: First cycle dsDNA was synthesized from 100 ng of total RNA extract using random hexamer primers tagged with T7 promoter sequence and SuperScript II (Invitrogen, Carlsbad CA) and then DNA Polymerase 1. Anti-sense cRNA was then synthesized using T7 polymerase and combined with SuperScript II, dUTP (+dNTP), and random hexamers to synthesize sense strand cDNA incorporating uracil.
- a combination of uracil DNA glycosylase (UDG) and apurinic/ apyrimidinic endonuclease1 (APE 1) were used to fragment the DNA product.
- the DNA was biotin labelled by terminal deoxynucleotidyl transferase (TdT) with the Affymetrix proprietary DNA Labeling Reagent covalently linked to biotin.
- TdT terminal deoxynucleotidyl transferase
- Hybridization to the Custom Chip CG_AGPa520460F was carried out at 45° C for 16-18hours. Finally, the chips were washed, stained and scanned as above.
- Quantitative real time polymerase chain reaction was used to confirm particular gene expression discoveries using Applied Biosystems pre-designed and optimized TaqMan gene expression assays. The resulting expression levels were quantified as a ratio to three genes (HPRT, TBP and GAPDH) with literature reported low variance expression levels. Final results were reported using the ⁇ -cycle threshold method.
- Prior to Real-time PCR analysis 100ng of total RNA was subject to linear amplification using the QIAGEN QuantiTect Whole Transcriptome amplification kit (QIAGEN, Country) according to the manufacturer's instructions.
- RNA Prior to end-point PCR analysis 2ug of total RNA was subject to linear amplification a high capacity cDNA reverse transcription kit available from Applied Biosystems. 5 ⁇ l of the amplified, diluted (1:2) cDNA was then analysied in a 25 ⁇ l reaction volume by PCR using a PCR Master Mix (Promega) according to manufacturer's recommendation. 2.5 ⁇ l of the amplified products were analysed on 2% agarose E-gel (Invitrogen) along with a 100-base pair DNA Ladder Marker.
- the gene hCG_1815491 is currently represented in NCBI as a single RefSeq sequence, XM_93911.
- the RefSeq sequence of hCG_1815491 is based on 89 GenBank accessions from 83 cDNA clones. Prior to March 2006, these clones were predicted to represent two overlapping genes, LOC388279 and LOC650242 (the latter also known as hCG_1815491). In March 2006, the human genome database was filtered against clone rearrangements, co-aligned with the genome and clustered in a minimal non-redundant way.
- LOC388272 and LOC650242 were merged into one gene named hCG_1815491 (earlier references to hCG_1815491 are: LOC388279, hCG_1815491, LOC650242, X_944116, AF275804, X_373688).
- SEQ ID NO:1 which is defined by the genomic coordinates 8579310 to 8562303 on human chromosome 16 as defined by the NCBI contig reference NT_010498.15
- SEQ ID NO:1 We have conclusively demonstrated the utility of SEQ ID NO:1 to diagnose neoplasia.
- SEQ ID NO: I can be used to diagnose adenomas, benign neoplastic lesions that can lead to colorectal adenocarcinoma.
- SEQ ID NO:1 can be used to diagnose colorectal cancer itself. We hence claim this molecule for broad clinical utility.
- RNA variant SEQ ID NO:21 is by far the most pronounced differentially expressed variant of SEQ ID NO:1, and SEQ ID NO:21 appears to be sensitive and specific for colorectal benign pre-cancerous adenomas as well as colorectal carcinoma. Hence we claim diagnostic utility of SEQ ID NO:21 for detection of colorectal neoplasia.
- RNA variant SEQ ID NO:23, derived from alternative splicing of SEQ ID NO: 1.
- This RNA variant is the result of an unprecedented splicing of map regions 8577328 - 8576605 and 8573324 - 8573212.
- We use this example to claim diagnostic utility of any combinations of nucleotide segments derived from SEQ ID NO:1.
- the gene expression of human hCG_1815491 was measured by determining the hybridization of RNA extracted from clinical specimens to Affymetrix oligonucleotide probesets, designated 238021_s_at and 238022_at, FIGURE 1 .
- the clinical specimens included a total of 454 colorectal tissues derived from 161 adenocarcinoma, 29 adenoma, 42 colitis and 222 non-diseased subjects
- transcripts derived from the human gene hCG-1815491 have diagnostic utility for identification of colorectal neoplasia.
- End-point PCR using the oligonucleotide sequence primers, 5'-TAACTCGAATTCATGTTGCTGAAATTCATCCCA (located in SEQ ID NO:6) and 5'-CACGATAAGCTTTTATTATAGTCTATAAACAGGAATACCCAAAACATA TTTAAACC (located in (SEQ ID NO:18), was performed to measure the RNA expression level from map region 8573246 to 88567197 within (SEQ ID NO:1 in a total of 71 colorectal tissue specimens: 30 non-diseased controls, 21 adenoma tissues and 20 Adenocarcinoma tissues, FIGURE 2 .
- End-point PCR demonstrated the appearance of four major products that were present in essentially all adenomas and adenocarcinoma colon tissue specimens. Most colon tissue samples from non-disease control specimens produced none or a limited subset of the PCR products.
- the multiple PCR bands included an approximately 284 base pair product that is the predicted size from the RefSeq NCBI hCG_1815491 entry as well as other bands presumed to arise from alternative splicing,
- SEQ ID NO:1 that contains map region 8573246 to 88567197 has diagnostic utility as means for detection of colorectal neoplasia.
- Quantitative real-time PCR using the same oligonucleotide sequence primers as described in Example 2, 5'-TAACTGG AATTCATGTTGGCTGAAATTCATCCCA and 5'-CACGATAAGCTTTTATTATAGTCTATAAACAGGAATACCCAAAACATA TTTAAACC, was performed to measure the RNA concentration level of SEQ ID NO:1 transcripts derived from map region 8573246 to 88567197 in a total of 71 colorectal tissue specimens: 30 non-diseased controls, 21 adenoma tissues and 20 adenocarcinoma tissues, FIGURE 3 . The figure shows that most normal tissues expressed low or non-detectable levels of transcripts by contrast to adenoma and adenocarcinoma tissues nearly expressed moderate to high levels of transcripts from SEQ ID NO:1.
- SEQ ID NO:1 that contains map region 8573246 to 88567197 has diagnostic utility as means as detection of colorectal neoplasia.
- cDNA clones from NCBI/Aceview were used to gather information regarding predicted RNA transcripts derived from hCG_1815491, FIGURE 4 & TABLE 1. None of the reported clones were derived from normal or neoplastic colon tissues.
- Oligonucleotide sequence primer sets were generated to each of the predicted 10 hCG_1815491 RNA variants (Table 5) and end-point PCR using these primer sets was performed to measure the existence of the ten [10] hCG_1815491 transcript variants in a total of 72 colorectal tissue specimens from 30 non-disease, 21 adenoma and 21 adenocarcinoma subjects.
- RNA transcripts The differential expression of the 10 predicted RNA transcripts, as determined using transcript specific primers, is exemplified in Figure 5 and Table 2. Differential expression as measured by end-point PCR was observed for several of the 10 RNA variants (TABLE 2) e.g. SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:27 and in particular SEQ ID NO:21 was the best one.
- RNA variants derived from SEQ ID NO:1 exist and they are generated through alternative usage of nucleotide segments in SEQ ID NO: 1.
- SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:27 but in particular SEQ ID NO:21 have diagnostic utility for detection of colorectal neoplasia.
- Quantitative Real-Time PCR was performed to measure the concentration level of RNA variants derived from map region 8579310 to 8562303 on the minus strand of human chromosome 16 in a total of 72 colorectal tissue specimens from 30 non-disease controls, 21 adenoma and 21 adenocarcinoma subjects. Quantitative differences were observed for several of the transcripts, and an example of the quantitative expression profile of SEQ ID NO:21 is given in FIGURE 6 .
- End-point PCR using a forward primer spanning the splice junction of SEQ ID NO:4 and SEQ ID NO:5, 5'- GGCGGAGGAGAGGTGAGC, with a reverse primer 5'-GCTGACAGCATCCA AATGTATTATG hybridizing to SEQ ID NO:6 was performed to demonstrate a novel RNA variant derived from alternative splicing of map region 8576892 - 8576605 with 8573324 - 8573280 , FIGURE 7 .
- the novel RNA variant named SEQ ED NO:23, appeared up-regulated in colorectal tissue specimens from 3 adenoma and 3 adenocarcinoma subjects but not in 2 non-disease controls, FIGURE 7 .
- SEQ ID NO:23 represents a novel RNA variant derived from SEQ ID NO:1. While new sequence data is common with respect to the human genome project, we have identified that this transcript designated SEQ ID NO:23 is a splice variant diagnostic of colorectal neoplasia.
- map region 8577414 to 8566289 has diagnostic utility for identification of colorectal neoplasia.
- Affymetrix probesets 3692525 (SEQ ID NO:6), 3692524 (SEQ ID NO:9), 3692519 (SEQ ID NO: 18), 3692520 (SEQ ID NO: 17), 3692523 and 3692522 (SEQ ID NO: 15), and 3692521 (SEQ ID NO: 13) can be used to diagnose adenomas, benign neoplastic lesions that can lead to colorectal adenocarcinoma.
- these probesets can be used to diagnose colorectal cancer itself.
- FIGURE 2 8579310-8562303 SEQ ID NO:21 E2b-E3-E5a-E6-E7a 8576878 - 8576605 8573324 - 8573212 8571761 - 8571696 8568521-8568409 8567320-8566974 SEQ ID NO:22 E2b-E3-E5a-E6c-E7a 8576878 - 8576605 8573324 - 8573212 8571761 - 8571696 8568449 - 8568409 8567320 - 8566974 SEQ ID NO:23 E2a-E2bE3 8577328 - 8576605 8573324 - 8573212 SEQ ID NO:24 ESb - E6-E7a 8571889 - 8571696 85685
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (17)
- Procédé de dépistage pour le commencement d'un néoplasme du gros intestin ou de surveillance d'un individu pour la présence d'un néoplasme du gros intestin, ledit procédé comprenant :(i) la mesure du taux d'expression de hCG_1815491 dans un échantillon biologique provenant dudit individu dans lequel un taux d'expression plus élevé de hCG_1815491 par rapport à des taux témoins indique une cellule néoplasique du gros intestin ou une cellule prédisposée au commencement d'un état néoplasique ; ou(ii) la mesure du taux d'expression d'un gène comprenant une séquence de nucléotides telle que représentée dans SEQ ID NO : 1 ou une séquence présentant une similarité d'au moins 90 % avec SEQ ID NO : 1 sur la longueur du gène dans un échantillon biologique provenant dudit individudans lequel un taux d'expression plus élevé dudit gène ou d'un variant de celui-ci par rapport à des taux témoins indique une cellule néoplasique du gros intestin, et dans lequel l'échantillon biologique est un échantillon fécal, un lavement, une résection chirurgicale du gros intestin, une biopsie de tissu du gros intestin ou un échantillon de sang.
- Procédé selon la revendication 1, ledit procédé comprenant la mesure du taux d'expression d'un ou de plusieurs produits de transcription d'ARNm, lesdits produits de transcription comprenant une séquence d'ARN sélectionnée parmi :(i) une séquence d'ARN caractérisée par la séquence d'une parmi :• SEQ ID NO : 21, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 22, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 23, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 24, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 25, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 26, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 27, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 28, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 29, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 30, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou• SEQ ID NO : 31, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence.(ii) une séquence d'ARN caractérisée par la séquence d'une parmi :• SEQ ID NO : 21, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 24, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 27, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 22, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 23, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 30, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 31, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou• SEQ ID NO : 25, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence.(iii) une séquence d'ARN caractérisée par la séquence d'une parmi :• SEQ ID NO : 21, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 24, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 27, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou• SEQ ID NO : 22, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence.
- Procédé de dépistage pour le commencement d'un néoplasme du gros intestin chez un individu, ledit procédé comprenant la mesure du taux d'expression d'un produit de transcription d'ARN, ledit produit de transcription comprenant un ou plusieurs segments d'exon sélectionnés parmi :(i) un segment d'exon défini par SEQ ID NO : 2, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(ii) un segment d'exon défini par SEQ ID NO : 3, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iii) un segment d'exon défini par SEQ ID NO : 4, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iv) un segment d'exon défini par SEQ ID NO : 5, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(v) un segment d'exon défini par SEQ ID NO : 6, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vi) un segment d'exon défini par SEQ ID NO : 7, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vii) un segment d'exon défini par SEQ ID NO : 8, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(viii) un segment d'exon défini par SEQ ID NO : 9, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(ix) un segment d'exon défini par SEQ ID NO : 10, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(x) un segment d'exon défini par SEQ ID NO : 11, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xi) un segment d'exon défini par SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xii) un segment d'exon défini par SEQ ID NO : 13, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xiii) un segment d'exon défini par SEQ ID NO : 14, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xiv) un segment d'exon défini par SEQ ID NO : 15, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xv) un segment d'exon défini par SEQ ID NO : 16, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xvi) un segment d'exon défini par SEQ ID NO : 17, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xvii) un segment d'exon défini par SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xviii) un segment d'exon défini par SEQ ID NO : 19, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou(xix) un segment d'exon défini par SEQ ID NO : 20, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquencedans un échantillon biologique provenant dudit individu dans lequel un taux plus élevé dudit produit de transcription d'ARN ou dudit variant de celui-ci par rapport à des taux témoins indique une cellule néoplasique du gros intestin, et dans lequel l'échantillon biologique est un échantillon fécal, un lavement, une résection chirurgicale du gros intestin, une biopsie de tissu du gros intestin ou un échantillon de sang.
- Procédé selon la revendication 3 dans lequel ledit produit de transcription comprend un ou plusieurs segments d'exon sélectionnés parmi :(i) un segment d'exon défini par SEQ ID NO : 3, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(ii) un segment d'exon défini par SEQ ID NO : 4, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iii) un segment d'exon défini par SEQ ID NO : 5, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iv) un segment d'exon défini par SEQ ID NO : 6, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(v) un segment d'exon défini par SEQ ID NO : 7, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vi) un segment d'exon défini par SEQ ID NO : 8, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vii) un segment d'exon défini par SEQ ID NO : 9, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou(viii) un segment d'exon défini par SEQ ID NO : 10, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(ix) un segment d'exon défini par SEQ ID NO : 11, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(x) un segment d'exon défini par SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xi) un segment d'exon défini par SEQ ID NO : 13, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xii) un segment d'exon défini par SEQ ID NO : 14, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xiii) un segment d'exon défini par SEQ ID NO : 15, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xiv) un segment d'exon défini par SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(xv) un segment d'exon défini par SEQ ID NO : 19, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence.
- Procédé selon la revendication 4 dans lequel ledit produit de transcription est sélectionné parmi :(i) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 5, SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(ii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 5, SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 14, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(iii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 3 et SEQ ID NO : 6, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(iv) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 11, SEQ ID NO : 12 et SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(v) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 4 et SEQ ID NO : 7, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(vi) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 13, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(vii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 6 et SEQ ID NO : 8, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(viii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 19 et SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(ix) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 15 et SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(x) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 6 et SEQ ID NO : 9, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences ou(xi) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 4, SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences.
- Procédé selon la revendication 3 dans lequel ledit produit de transcription comprend un ou plusieurs segments d'exon sélectionnés parmi :(i) un segment d'exon défini par SEQ ID NO : 5, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(ii) un segment d'exon défini par SEQ ID NO : 6, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iii) un segment d'exon défini par SEQ ID NO : 8, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(iv) un segment d'exon défini par SEQ ID NO : 10, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(v) un segment d'exon défini par SEQ ID NO : 11, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vi) un segment d'exon défini par SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence(vii) un segment d'exon défini par SEQ ID NO : 14, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou(viii) un segment d'exon défini par SEQ ID NO : 18, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence.
- Procédé selon la revendication 4 dans lequel ledit produit de transcription est sélectionné parmi :(i) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 5, SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 12, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(ii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 5, SEQ ID NO : 6, SEQ ID NO : 10 et SEQ ID NO : 14, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences(iii) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 11, SEQ ID NO : 12, SEQ ID NO : 18 et SEQ ID NO : 24, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences ou(iv) un produit de transcription d'ARN qui comprend chacun des segments d'exon définis par SEQ ID NO : 6 et SEQ ID NO : 8, ou une séquence présentant une similarité d'au moins 90 % sur la longueur de ces séquences.
- Procédé selon l'une quelconque des revendications 3 à 7 dans lequel les segments d'exon desdits produits de transcription sont épissés de manière à ce qu'ils soient joints.
- Procédé de dépistage pour le commencement d'un néoplasme du gros intestin chez un individu, ledit procédé comprenant la mesure du taux d'expression d'un ou de plusieurs produits de transcription d'ARN, lesdits produits de transcription comprenant une séquence d'ARN sélectionnée parmi :(i) une séquence d'ARN caractérisée par la séquence d'une parmi :• SEQ ID NO : 21 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 24 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 25 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 26 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 29 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 30 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 31 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ou(ii) une séquence d'ARN caractérisée par la séquence d'une parmi :dans un échantillon biologique provenant dudit individu dans lequel un taux d'expression plus élevé des gènes ou des produits de transcription du groupe (i) et/ou du groupe (ii) par rapport aux taux de fond indique une cellule néoplasique ; et dans lequel l'échantillon biologique est un échantillon fécal, un lavement, une résection chirurgicale du gros intestin, une biopsie de tissu du gros intestin ou un échantillon de sang.• SEQ ID NO : 22 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 23 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence• SEQ ID NO : 27 ou une séquence présentant une similarité d'au moins 90 % sur la longueur de la séquence ;
- Procédé selon la revendication 9 dans lequel lesdites séquences d'ARN sont caractérisées par la séquence de SEQ ID NO : 21 ou de SEQ ID NO : 22.
- Procédé selon l'une quelconque des revendications 1 à 10 dans lequel ledit taux d'expression est une expression d'ARNm.
- Procédé selon l'une quelconque des revendications 1 à 10 dans lequel ladite similarité d'au moins 90 % est de 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 % ou 99 %.
- Procédé selon l'une quelconque des revendications 1 à 12 dans lequel ledit taux d'expression est évalué par l'analyse d'une expression d'ARN ou d'une expression de protéine.
- Procédé selon l'une quelconque des revendications 1 à 8 dans lequel ledit taux témoin est un taux non néoplasique.
- Procédé selon l'une quelconque des revendications 1 à 14 dans lequel ladite cellule néoplasique est un adénome ou un adénocarcinome.
- Procédé selon la revendication 15 dans lequel ladite cellule est une cellule colorectale.
- Procédé selon l'une quelconque des revendications 1 à 16 dans lequel ledit individu est un humain.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98211407P | 2007-10-23 | 2007-10-23 | |
PCT/AU2008/001569 WO2009052571A1 (fr) | 2007-10-23 | 2008-10-23 | Procédé de diagnostic de néoplasmes |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2215261A1 EP2215261A1 (fr) | 2010-08-11 |
EP2215261A4 EP2215261A4 (fr) | 2011-01-12 |
EP2215261B1 true EP2215261B1 (fr) | 2018-02-21 |
Family
ID=40578971
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16160209.9A Active EP3056576B1 (fr) | 2007-10-23 | 2008-10-23 | Procédé permettant de diagnostiquer des néoplasmes |
EP08843297.6A Active EP2215261B1 (fr) | 2007-10-23 | 2008-10-23 | Procédé de diagnostic de néoplasmes |
EP08842750A Withdrawn EP2215258A4 (fr) | 2007-10-23 | 2008-10-23 | Procédé de diagnostic de néoplasmes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16160209.9A Active EP3056576B1 (fr) | 2007-10-23 | 2008-10-23 | Procédé permettant de diagnostiquer des néoplasmes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08842750A Withdrawn EP2215258A4 (fr) | 2007-10-23 | 2008-10-23 | Procédé de diagnostic de néoplasmes |
Country Status (4)
Country | Link |
---|---|
US (6) | US20110160072A1 (fr) |
EP (3) | EP3056576B1 (fr) |
AU (2) | AU2008316317B2 (fr) |
WO (2) | WO2009052571A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL301804A (en) | 2006-05-18 | 2023-05-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2009052571A1 (fr) | 2007-10-23 | 2009-04-30 | Clinical Genomics Pty. Ltd. | Procédé de diagnostic de néoplasmes |
JP5361858B2 (ja) * | 2008-02-17 | 2013-12-04 | 昭平 森 | 紙を綴じ込むための綴じ部材及び綴じ部材を用いた紙製品 |
WO2009158620A2 (fr) * | 2008-06-26 | 2009-12-30 | Dana-Farber Cancer Institute, Inc. | Signatures et déterminants associés à des métastases, et leurs procédés d'utilisation |
WO2010045470A2 (fr) * | 2008-10-15 | 2010-04-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, et procédés d'identification, d'évaluation, de prévention, et de thérapie de troubles hépatiques |
JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
US8211659B2 (en) * | 2008-11-07 | 2012-07-03 | Tungs' Taichung Metroharbor Hospital | Methods and kits for detection of cancer metastasis |
JP2012508577A (ja) | 2008-11-12 | 2012-04-12 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 表現型を決定するためのエキソソームの使用方法およびそのシステム |
WO2010135786A1 (fr) * | 2009-05-29 | 2010-12-02 | Clinical Genomics Pty. Ltd. | Procédé permettant de diagnostiquer des néoplasmes et molécules destinées à être utilisées dans ce procédé |
WO2011050407A1 (fr) * | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Procédés de diagnostic et de pronostic de polypes du côlon |
WO2011106583A1 (fr) * | 2010-02-26 | 2011-09-01 | Ventana Medical Systems, Inc. | Sondes polytag |
CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
EP2611933A1 (fr) * | 2010-09-02 | 2013-07-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédé de pronostic de la progression du cancer |
WO2012044167A2 (fr) * | 2010-09-28 | 2012-04-05 | Agendia N.V. | Procédés et moyens de typage d'un échantillon comprenant des cellules cancéreuses basés sur les voies de transduction du signal oncogène |
WO2012054975A1 (fr) | 2010-10-28 | 2012-05-03 | Clinical Genomics Pty. Ltd. | Procédé d'enrichissement en microvésicules |
WO2012125411A1 (fr) * | 2011-03-11 | 2012-09-20 | Metamark Genetics, Inc. | Procédés de prédiction du pronostic dans le cancer |
US9585953B2 (en) | 2011-03-22 | 2017-03-07 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
CA2840946A1 (fr) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Procedes et compositions permettant le traitement et le diagnostic du cancer |
GB201112622D0 (en) * | 2011-07-22 | 2011-09-07 | Ucl Business Plc | Pathogen screening |
ES2398328B1 (es) * | 2011-08-09 | 2014-02-05 | Oncomatrix, S.L. | Métodos y productos para el diagnóstico in vitro, pronóstico in vitro y desarrollo de fármacos contra carcinomas invasivos. |
CA2844126C (fr) | 2011-08-18 | 2019-06-18 | Ming-Chung Jiang | Proteine membranaire de microvesicule et application associee |
AU2012301664A1 (en) * | 2011-08-31 | 2014-02-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
WO2013033629A2 (fr) * | 2011-08-31 | 2013-03-07 | Oncocyte Corporation | Méthodes et compositions pour le traitement et le diagnostic du cancer colorectal |
MX368034B (es) | 2012-05-11 | 2019-09-17 | Clinical Genomics Pty Ltd | Panel de marcadores genéticos para el diagnóstico de cáncer colorrectal. |
WO2014168968A1 (fr) * | 2013-04-10 | 2014-10-16 | University Of Houston System | Magnétisation résiduelle induite par échange pour la détection sans étiquettes d'adn, de micro-arn, et de biomarqueurs de liaison à l'adn/arn |
US10754250B2 (en) * | 2013-07-31 | 2020-08-25 | The Regents Of The University Of California | DNA double-write/double binding identity |
US20170220743A1 (en) * | 2014-02-19 | 2017-08-03 | Indiana University Research And Technology Corporation | Tracking real-time assessment of quality monitoring in endoscopy |
CN106399464A (zh) * | 2015-07-31 | 2017-02-15 | 复旦大学 | 一种人结直肠癌分子标志物col3a1及其用途 |
CN107158361B (zh) * | 2017-05-25 | 2019-03-12 | 温州医科大学 | Reg1a蛋白在制备治疗和/或预防视网膜细胞凋亡药物中的应用 |
CN107858423B (zh) * | 2017-12-22 | 2020-06-30 | 苏州大学 | 用于预测心源性猝死易感性的试剂盒 |
US11198911B2 (en) | 2018-03-08 | 2021-12-14 | University Of Notre Dame Du Lac | Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon |
KR20210016362A (ko) | 2018-05-29 | 2021-02-15 | 투룬 일리오피스토 | 결장암 예측 바이오마커로서의 l1td1 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5045453A (en) * | 1988-08-26 | 1991-09-03 | Dianon Systems, Inc. | Method for determining sialic acid in plasma |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
AU2001252945A1 (en) * | 2000-03-24 | 2001-10-08 | Corixa Corporation | Compositions and methods for therapy and diagnosis of colon cancer |
US20060035237A1 (en) * | 2002-08-26 | 2006-02-16 | Markowitz Sanford D | Methods and compositions for categorizing patients |
AU2002351828A1 (en) * | 2001-11-05 | 2003-05-19 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
US20060188889A1 (en) * | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
CA2514187A1 (fr) * | 2003-01-24 | 2004-08-12 | Bayer Pharmaceuticals Corporation | Profils d'expression destines au cancer du colon et procedes d'utilisation |
US20070037204A1 (en) * | 2003-08-08 | 2007-02-15 | Hiroyuki ABURANTAI | Gene overexpressed in cancer |
BRPI0510883B8 (pt) * | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
AU2005300688B2 (en) * | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
AU2006340769A1 (en) * | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
CA2660286A1 (fr) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Proteines specifiques d'organes et procedes d'utilisation |
WO2009052571A1 (fr) | 2007-10-23 | 2009-04-30 | Clinical Genomics Pty. Ltd. | Procédé de diagnostic de néoplasmes |
KR101115449B1 (ko) * | 2011-03-17 | 2012-03-15 | 한국생명공학연구원 | 대장암 진단용 조성물 및 그 용도 |
WO2013052480A1 (fr) * | 2011-10-03 | 2013-04-11 | The Board Of Regents Of The University Of Texas System | Score de risque pronostique de cancer du côlon basé sur des marqueurs |
-
2008
- 2008-10-23 WO PCT/AU2008/001569 patent/WO2009052571A1/fr active Application Filing
- 2008-10-23 AU AU2008316317A patent/AU2008316317B2/en active Active
- 2008-10-23 EP EP16160209.9A patent/EP3056576B1/fr active Active
- 2008-10-23 US US12/739,559 patent/US20110160072A1/en not_active Abandoned
- 2008-10-23 AU AU2008316319A patent/AU2008316319A1/en not_active Abandoned
- 2008-10-23 WO PCT/AU2008/001571 patent/WO2009052573A1/fr active Application Filing
- 2008-10-23 EP EP08843297.6A patent/EP2215261B1/fr active Active
- 2008-10-23 US US12/739,580 patent/US20100292094A1/en not_active Abandoned
- 2008-10-23 EP EP08842750A patent/EP2215258A4/fr not_active Withdrawn
-
2014
- 2014-11-13 US US14/540,583 patent/US20150159223A1/en not_active Abandoned
-
2015
- 2015-08-12 US US14/824,522 patent/US10344334B2/en active Active
-
2016
- 2016-12-16 US US15/381,895 patent/US20170211152A1/en not_active Abandoned
-
2017
- 2017-11-10 US US15/809,162 patent/US20180100200A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
"Shows that the Affymetrix array Human Exon 1.0 comprises probes for SEQ ID NO:21-31 of EP08 843297", PUBLICATION DATE TAKEN FROM PAPER XP 055036877 IN WHICH THIS ARRAY WAS USED, 5 June 2007 (2007-06-05), XP055036885, Retrieved from the Internet <URL:www> [retrieved on 20120831] * |
"Shows that the Affymetrix array Human Exon 1.0 comprises probes for SEQ ID NO:2-20 of EP08 843297", PUBLICATION DATE TAKEN FROM PAPER XP 055036877 IN WHICH THIS ARRAY WAS USED, 5 June 2007 (2007-06-05), XP055036893, Retrieved from the Internet <URL:www> [retrieved on 20120831] * |
GARDINA PAUL J ET AL: "Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 7, no. 1, 27 December 2006 (2006-12-27), pages 325, XP021022290, ISSN: 1471-2164, DOI: 10.1186/1471-2164-7-325 * |
R YOSHIDA ET AL: "A statistical framework for genome-wide discovery of biomarker splice variations with GeneChip Human Exon 1.0 ST Arrays", GENOME INFORM., vol. 17, no. 1, 1 January 2006 (2006-01-01), pages 88 - 99, XP055036922 * |
R. S. HUANG ET AL: "A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 23, 5 June 2007 (2007-06-05), pages 9758 - 9763, XP055036877, ISSN: 0027-8424, DOI: 10.1073/pnas.0703736104 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009052573A1 (fr) | 2009-04-30 |
EP2215258A4 (fr) | 2010-12-01 |
EP2215258A1 (fr) | 2010-08-11 |
US20160130657A1 (en) | 2016-05-12 |
WO2009052571A1 (fr) | 2009-04-30 |
AU2008316317B2 (en) | 2015-04-30 |
US20110160072A1 (en) | 2011-06-30 |
EP2215261A4 (fr) | 2011-01-12 |
EP2215261A1 (fr) | 2010-08-11 |
EP3056576A2 (fr) | 2016-08-17 |
EP3056576A3 (fr) | 2016-09-28 |
US20170211152A1 (en) | 2017-07-27 |
US20180100200A1 (en) | 2018-04-12 |
AU2008316319A1 (en) | 2009-04-30 |
US20100292094A1 (en) | 2010-11-18 |
US10344334B2 (en) | 2019-07-09 |
AU2008316317A1 (en) | 2009-04-30 |
EP3056576B1 (fr) | 2019-02-13 |
US20150159223A1 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10344334B2 (en) | Method of diagnosing neoplasms | |
JP6106636B2 (ja) | 2型腫瘍症(neoplasms−ii)の診断法 | |
EP2767595A1 (fr) | Procédé de détection | |
AU2020201779B2 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
AU2019222816B2 (en) | A method of diagnosing neoplasms - II | |
AU2015203005B2 (en) | A method of diagnosing neoplasms | |
WO2010135786A1 (fr) | Procédé permettant de diagnostiquer des néoplasmes et molécules destinées à être utilisées dans ce procédé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100521 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20101210 |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20120913 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170904 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008054125 Country of ref document: DE Ref country code: AT Ref legal event code: REF Ref document number: 971781 Country of ref document: AT Kind code of ref document: T Effective date: 20180315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180221 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 971781 Country of ref document: AT Kind code of ref document: T Effective date: 20180221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180521 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180521 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008054125 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20181122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20181031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181023 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181023 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181023 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081023 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180621 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230608 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230831 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230911 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230830 Year of fee payment: 16 |